HC Wainwright Has Strong Estimate for ASMB FY2028 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Analysts at HC Wainwright increased their FY2028 earnings per share (EPS) estimates for Assembly Biosciences in a report released on Wednesday, September 9th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will earn $0.84 per share for the year, up from their prior forecast of $0.80. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $2.28 per share. HC Wainwright also issued estimates for Assembly Biosciences’ FY2030 earnings at $3.32 EPS.

A number of other equities research analysts also recently issued reports on ASMB. Zacks Research upgraded shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Guggenheim reaffirmed a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. Mizuho set a $53.00 target price on shares of Assembly Biosciences in a research report on Tuesday, September 1st. UBS Group assumed coverage on Assembly Biosciences in a report on Tuesday, September 1st. They issued a “buy” rating and a $52.00 price target for the company. Finally, Wall Street Zen downgraded Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Assembly Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $45.60.

Assembly Biosciences Stock Down 6.8%

NASDAQ:ASMB opened at $32.87 on Thursday. Assembly Biosciences has a fifty-two week low of $20.23 and a fifty-two week high of $39.71. The stock has a market cap of $669.23 million, a PE ratio of 32.23 and a beta of 1.13. The firm’s fifty day simple moving average is $29.68 and its 200-day simple moving average is $28.36.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP increased its holdings in shares of Assembly Biosciences by 671.5% during the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock worth $11,903,000 after purchasing an additional 377,000 shares during the period. Stempoint Capital LP boosted its stake in Assembly Biosciences by 18.3% in the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock valued at $5,146,000 after buying an additional 28,707 shares in the last quarter. Eversept Partners LP bought a new stake in shares of Assembly Biosciences in the 4th quarter worth about $5,431,000. 683 Capital Management LLC bought a new position in shares of Assembly Biosciences in the fourth quarter valued at approximately $948,000. Finally, Squarepoint Ops LLC raised its position in Assembly Biosciences by 43.7% in the 2nd quarter. Squarepoint Ops LLC now owns 34,214 shares of the biopharmaceutical company’s stock valued at $940,000 after purchasing an additional 10,410 shares during the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.